RESEARKA

The global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations.

Citation Support

• source_1 Movahedian 2025
• source_2 Kopytek 2025
• source_3 Kabthymer 2024
• source_4 Li 2025
• source_5 Dahlen 2025